Teva Pharmaceutical Industries Investor Presentation — May 2024

Document content

May 8, 2024First Quarter 2024

ResultsTeva Pharmaceutical Industries Ltd.2 |This presentation contains forward -looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , which are based on management ’s current beliefs and expectations and are subject to substantial risks and

uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significant ly from that expressed or implied by such forward -looking statements. Important factors that could cause or contribute to

such differences include risks relating to:

• our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic product s; concentration of our customer base and commercial alliances among our customers; delays in launches of new

generic products; our ability to develop and commercialize biopharmaceutical products; competition for our innovative medicin es; our ability to achieve expected results from investments in our product pipeline; our ability to develop and

commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines

and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of gene rics medicines; and the effectiveness of our patents and other measures to protect our intellectual property rights,

including any potential challenges to our Orange Book patent listings in the U.S.;

• our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, may result in a future downgrade of our credit ratings; and our inability to raise debt or

borrow funds in amounts or on terms that are favorable to us;

• our business and operations in general, including: the impact of global economic conditions and other macroeconomic developme nts and the governmental and societal responses thereto; the widespread outbreak of an illness or any other

communicable disease, or any other public health crisis; effectiveness of our optimization efforts; our ability to attract, h ire, integrate and retain highly skilled personnel; interruptions in our supply chain or problems with internal or third party

manufacturing; disruptions of information technology systems; breaches of our data security; challenges associated with condu cting business globally, including political or economic instability, major hostilities or terrorism, such as the

ongoing conflict between Russia and Ukraine and the state of war declared in Israel; costs and delays resulting from the exte nsive pharmaceutical regulation to which we are subject; our ability to successfully bid for suitable acquisition targets